Mirati Therapeutics (MRTX) stock Forecast for 2021 – 2025

Mirati Therapeutics (MRTX) stock Forecast for 2022 – 2026

Last update: November 27, 2022 (07:09)

Sector: Healthcare

The share price of Mirati Therapeutics, Inc. (MRTX) now

What analysts predict: $115.06

52-week high/low: $154.17 / $32.96

50/200 Day Moving Average: $69.7 / $72.77

This figure corresponds to the average price over the previous 50/200 days. For Mirati Therapeutics stocks, the 50-day moving average is the support level today.

For Mirati Therapeutics stocks, the 200-day moving average is the support level today.

Are you interested in Mirati Therapeutics, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Mirati Therapeutics stock price in 2022, 2023, 2024, 2025, 2026. How much will one Mirati Therapeutics share be worth in 2022 - 2026?

When should I take profit in Mirati Therapeutics stock? When should I record a loss on Mirati Therapeutics stock? What are analysts' forecasts for Mirati Therapeutics stock? What is the future of Mirati Therapeutics stock? We forecast Mirati Therapeutics stock performance using neural networks based on historical data on Mirati Therapeutics stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.

Mirati Therapeutics stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2022, 2023, 2024, 2025 and 2026) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Mirati Therapeutics shares. This happens once a day.




Historical and forecast chart of Mirati Therapeutics stock

The chart below shows the historical price of Mirati Therapeutics stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Mirati Therapeutics stock price can be found in the table below.

Long-term forecasts by years.

Mirati Therapeutics daily forecast for a month

Date Target Pes. Opt. Vol., %
Nov 29 96.87 94.76 97.78 3.18
Nov 30 95.61 93.50 96.41 3.11
Dec 01 95.51 94.01 97.52 3.73
Dec 02 96.61 94.75 99.32 4.82
Dec 03 96.38 95.70 97.96 2.36
Dec 04 96.38 95.40 97.05 1.73
Dec 05 95.97 94.66 97.32 2.80
Dec 06 96.91 94.61 98.20 3.80
Dec 07 94.50 91.86 95.23 3.67
Dec 08 91.89 89.96 93.21 3.61
Dec 09 92.34 91.37 94.05 2.94
Dec 10 90.76 88.22 93.17 5.62
Dec 11 93.46 92.67 95.65 3.21
Dec 12 94.86 92.74 96.52 4.08
Dec 13 93.34 92.16 95.66 3.79
Dec 14 94.45 92.03 95.51 3.77
Dec 15 93.52 92.77 95.55 3.00
Dec 16 93.10 91.14 95.70 5.01
Dec 17 94.53 93.41 95.89 2.66
Dec 18 94.89 92.70 96.95 4.59
Dec 19 95.33 92.69 97.56 5.26
Dec 20 95.96 93.98 98.65 4.97
Dec 21 97.91 95.99 99.69 3.86
Dec 22 98.80 97.59 100.18 2.66
Dec 23 101.57 98.72 103.70 5.04
Dec 24 104.37 102.22 105.84 3.54
Dec 25 102.11 101.14 103.29 2.12
Dec 26 103.82 102.88 105.75 2.79
Dec 27 102.70 100.29 104.60 4.30
Dec 28 104.46 103.55 106.62 2.97

Mirati Therapeutics Daily Price Targets


Mirati Therapeutics Stock Forecast 11-29-2022.

Forecast target price for 11-29-2022: $96.87.
Negative dynamics for Mirati Therapeutics shares will prevail with possible volatility of 3.086%.
Pessimistic target level: 94.76
Optimistic target level: 97.78

Mirati Therapeutics Stock Forecast 11-30-2022.

Forecast target price for 11-30-2022: $95.61.
Negative dynamics for Mirati Therapeutics shares will prevail with possible volatility of 3.020%.
Pessimistic target level: 93.50
Optimistic target level: 96.41

Mirati Therapeutics Stock Forecast 12-01-2022.

Forecast target price for 12-01-2022: $95.51.
Negative dynamics for Mirati Therapeutics shares will prevail with possible volatility of 3.599%.
Pessimistic target level: 94.01
Optimistic target level: 97.52

Mirati Therapeutics Stock Forecast 12-02-2022.

Forecast target price for 12-02-2022: $96.61.
Positive dynamics for Mirati Therapeutics shares will prevail with possible volatility of 4.596%.
Pessimistic target level: 94.75
Optimistic target level: 99.32

Mirati Therapeutics Stock Forecast 12-03-2022.

Forecast target price for 12-03-2022: $96.38.
Negative dynamics for Mirati Therapeutics shares will prevail with possible volatility of 2.307%.
Pessimistic target level: 95.70
Optimistic target level: 97.96

Mirati Therapeutics Stock Forecast 12-04-2022.

Forecast target price for 12-04-2022: $96.38.
Negative dynamics for Mirati Therapeutics shares will prevail with possible volatility of 1.703%.
Pessimistic target level: 95.40
Optimistic target level: 97.05

MRTX (MRTX) Monthly Stock Prediction for 2022

Month Target Pes. Opt. Vol., %
Dec. 78.01 70.75 81.75 13.45

Mirati Therapeutics forecast for this year


Mirati Therapeutics Stock Prediction for Dec 2022

An downtrend is forecast for this month with an optimal target price of $78.0061. Pessimistic: $70.75. Optimistic: $81.75



Mirati Therapeutics (MRTX) Monthly Stock Prediction for 2023

Month Target Pes. Opt. Vol., %
Jan 73.09 67.06 81.20 17.42
Feb 72.54 63.84 78.64 18.82
Mar 77.33 68.05 83.02 18.03
Apr 70.26 66.78 77.95 14.33
May 74.15 67.04 82.72 18.96
Jun 82.83 77.61 88.55 12.35
Jul 80.97 72.59 90.20 19.52
Aug 75.14 68.60 81.45 15.77
Sep 84.04 79.38 88.45 10.26
Oct 82.65 78.44 86.75 9.58
Nov 81.54 72.24 89.86 19.60
Dec 86.43 77.36 89.41 13.48

Mirati Therapeutics (MRTX) Monthly Stock Prediction for 2024

Month Target Pes. Opt. Vol., %
Jan 98.75 93.42 107.49 13.09
Feb 111.34 102.65 122.36 16.10
Mar 114.34 102.34 117.95 13.23
Apr 121.03 114.32 127.39 10.26
May 117.58 111.23 121.29 8.29
Jun 120.23 116.08 129.97 10.68
Jul 108.51 100.86 114.37 11.81
Aug 106.07 94.13 117.20 19.68
Sep 105.43 98.31 113.97 13.74
Oct 106.54 99.19 113.09 12.29
Nov 106.86 102.37 116.63 12.23
Dec 121.44 111.06 127.09 12.61

Mirati Therapeutics (MRTX) Monthly Stock Prediction for 2025

Month Target Pes. Opt. Vol., %
Jan 124.90 117.60 134.83 12.78
Feb 126.21 111.26 135.11 17.65
Mar 114.10 106.74 117.69 9.31
Apr 117.18 104.17 125.09 16.72
May 125.26 111.55 130.90 14.78
Jun 112.68 109.29 120.79 9.52
Jul 120.62 113.20 134.91 16.09
Aug 132.92 117.17 142.09 17.54
Sep 133.92 124.88 142.96 12.65
Oct 148.38 137.03 163.52 16.20
Nov 139.26 129.44 147.82 12.44
Dec 159.73 151.82 173.62 12.56

Mirati Therapeutics (MRTX) Monthly Stock Prediction for 2026

Month Target Pes. Opt. Vol., %
Jan 181.77 174.13 191.31 8.98
Feb 202.22 190.09 225.88 15.85
Mar 206.46 193.15 222.57 13.22
Apr 199.65 187.37 223.01 15.98
May 212.83 198.14 231.34 14.35
Jun 217.94 199.96 237.22 15.71
Jul 236.90 226.95 265.32 14.46
Aug 244.00 221.68 261.21 15.13
Sep 273.28 257.30 298.70 13.86
Oct 273.28 243.77 284.76 14.40
Nov 274.51 249.81 298.40 16.28
Dec 266.28 239.52 286.25 16.33

Mirati Therapeutics information and performance

Mirati Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is focused on developing a pipeline of targeted cancer drugs. The company is developing candidate products to combat genetic and immunological cancer promoters. Its clinical programs consist of two candidate products: MRTX849, a Kirsten rat sarcoma inhibitor (KRAS) G12C, and Sitravatinib, a multi-kinase inhibitor. His KRAS inhibitor program is focused on the discovery and development of small molecule compounds that target KRAS G12C and G12D. MRTX849 is designed to inhibit the KRAS G12C mutations that are present in patients with non-small cell lung cancer (NSCLC), adenocarcinoma, colorectal cancer (CRC), pancreatic cancer, and several other intractable cancers. Sitravatinib is a spectrally selective kinase inhibitor designed to inhibit receptor tyrosine kinases (RTKs) including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET.

Mirati Therapeutics Address

9393 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO, CA, US

Market Capitalization: 4 419 794 000 $

Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.

EBITDA: -742 340 992 $

EBITDA is earnings before interest, income tax and depreciation of assets.

PE Ratio: None

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: N/A

Price/earnings to growth

DPS: N/A

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: N/A

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: -11.96

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: -0.924
Trailing PE: -

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: -

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 277.1

Enterprise Value (EV) /Revenue

EV To EBITDA: -4.405

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 57587000

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A



Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.